STOCK TITAN

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Catalyst Pharmaceuticals (Nasdaq: CPRX) will release its Q2 2022 financial results after market close on August 9, 2022. A conference call and webcast are scheduled for August 10, 2022, at 8:30 AM ET, where management will discuss the results and provide a corporate update. The event can be accessed via the company's website, and a replay will be available for 30 days. Catalyst focuses on developing medicines for rare diseases, with its FDA-approved product FIRDAPSE® for Lambert-Eaton myasthenic syndrome.

Positive
  • Catalyst's focus on novel medicines for rare diseases could strengthen its market position.
  • FIRDAPSE is already FDA-approved and commercially available, indicating a successful product launch.
Negative
  • None.

The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET

CORAL GABLES, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022.

Catalyst's management team will host a conference call and webcast the following morning, Wednesday, August 10, 2022, at 8:30 AM ET to discuss the Company's financial results and provide a corporate update.

Conference Call & Webcast Details

Date/Time:August 10, 2022, at 8:30 AM ET
US/Canada Dial-in Number:(877) 407-8912
International Dial-in Number:(201) 689-8059
  

A webcast and accompanying materials will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for 30 days following the date of the event.

About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

For more information, visit the Company's website at www.catalystpharma.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2021 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.


FAQ

What are the financial results of Catalyst Pharmaceuticals for Q2 2022?

Catalyst Pharmaceuticals will release its Q2 2022 financial results on August 9, 2022.

When will Catalyst Pharmaceuticals host its conference call?

The conference call is scheduled for August 10, 2022, at 8:30 AM ET.

Where can I access the Catalyst Pharmaceuticals conference call?

You can access the conference call via the Catalyst Pharmaceuticals website in the Investors section.

What product does Catalyst Pharmaceuticals have approved by the FDA?

Catalyst Pharmaceuticals has FIRDAPSE® (amifampridine) Tablets 10 mg approved for the treatment of Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceutical Inc.

NASDAQ:CPRX

CPRX Rankings

CPRX Latest News

CPRX Stock Data

2.51B
111.77M
6.02%
82.24%
4.76%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CORAL GABLES